Brought to you by 
Dendreon nets in $46mm through private sale
10 Apr 2008
Executive Summary
Dendreon (immunotherapeutics for cancer) sold 8mm common shares at $5.92 apiece (a 24% premium) to an undisclosed institutional investor, netting about $46mm. The buyer also received seven-year warrants to purchase 8mm more shares at $20 each. Lazard was the placement agent.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Dendreon nets in $46mm through private sale
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice